1.
Ann Urol (Paris)
; 24(4): 340-4, 1990.
Article
in French
| MEDLINE
| ID: mdl-1699470
ABSTRACT
We present 271 prostatic adenocarcinomas with a follow-up of between 11.5 and 18 years, treated by palliative hormone therapy. Multivariate analysis defines three groups. Group 1 (78 cases): with a normal survival; Groups II and III: with poor survival. In this group, treatment is ineffective.